Prof Kantarjian speaks to ecancer about the results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukaemia with IDH 1/2 mutations.
This study was presented at ASH 2020, this year. In this interview Prof Kantarjian speaks about the rationale behind this study and some of the key results that were observed.
He says Ven Aza compared to Aza monotherapy resulted in higher response rates, longer DoR, and mOS among treatment-naïve patients with IDH1/2 mutations ineligible for intensive chemotherapy.
The safety profile or these drugs was also acceptable and no unexpected toxicities were noted with Ven Aza combination. He then talks about the future impact of the results from this study.
This program is funded in part via an independent grant from AbbVie. ecancer is editorially independent and there is no influence over content.